Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) posted its quarterly earnings results on Monday. The biotechnology company reported ($5.19) earnings per share for the quarter, missing the consensus estimate of ($3.71) by ($1.48), FiscalAI reports.
Aptevo Therapeutics Price Performance
Shares of APVO stock opened at $0.59 on Monday. The company’s fifty day simple moving average is $1.59 and its two-hundred day simple moving average is $4.01. Aptevo Therapeutics has a 52 week low of $0.59 and a 52 week high of $25.74. The stock has a market cap of $1.08 million, a P/E ratio of -0.01 and a beta of 1.65.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings cut shares of Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research report on Thursday, October 29th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, Aptevo Therapeutics currently has a consensus rating of “Sell”.
About Aptevo Therapeutics
Aptevo Therapeutics Inc. is a biotechnology company developing targeted immunotherapies for cancer and other serious diseases. The company is headquartered in Seattle, Washington, and was established in 2016 as a spin-off from Emergent BioSolutions. Aptevo’s research is based primarily on its ADAPTIR and ADAPTIR-FLEX antibody platforms, which are designed to create bispecific immune-cell engagers. These therapies are intended to connect immune cells with cancer cells or activate immune pathways to produce a targeted response.
Read More
- Five stocks we like better than Aptevo Therapeutics
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
